Wed, Aug 27, 2014, 6:22 AM EDT - U.S. Markets open in 3 hrs 8 mins

Recent

% | $
Quotes you view appear here for quick access.

Sanofi Message Board

  • dws.redsonja@verizon.net dws.redsonja May 14, 2011 12:10 AM Flag

    Weekly Roundup Jim Cramer 05/13/11 - 07:25 PM EDT

    Sanofi-Aventis (SNY:NYSE; $38.10; 2,500 shares; 3.01%; Sector: Health Care): Sanofi Pasteur, the company's vaccine division, announced that the FDA has approved its supplemental biologics license application for licensure of Fluzone Intradermal. The vaccine fights influenza virus subtypes A and B and is suitable for adults 18 through 64. This announcement was expected and highlights the company's effort to grow beyond just pharmaceuticals and into faster-growing segments -- vaccines, diabetes, generics and animal/consumer health. The trough year in earnings is coming in 2012, with Plavix/Iscover, Taxotere, Avapro/Avalide and Ambien CR all going off patent -- but beyond this well-expected period, the company has positioned itself for 5%-7% growth from 2013 to 2015. It has two analyst meetings upcoming (June 28 and Sept. 6) that will likely be positive catalysts for the shares. At 8x earnings, the stock remains attractive. I bought more this week and will continue to build up the position. My target is $45.

 
SNY
54.79+1.07(+1.99%)Aug 26 4:02 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.